| | | Single nucleotide variant (missense variant) | Central core myopathy +4 more | |
| | | Single nucleotide variant (missense variant) | Malignant hyperthermia, susceptibility to, 1 | |
| | | Single nucleotide variant (missense variant) | succinylcholine response - Toxicity +7 more | GPathogenic; drug response |
| | | Single nucleotide variant (missense variant) | Central core myopathy +8 more | |
| | | Single nucleotide variant (missense variant) | Malignant hyperthermia of anesthesia | |
| | | Single nucleotide variant (missense variant) | Malignant hyperthermia, susceptibility to, 1 | |
| | | Single nucleotide variant (missense variant) | Malignant hyperthermia, susceptibility to, 1 | |
| | LOC126862902, RYR1 (S2776F) | Single nucleotide variant (missense variant) | Malignant hyperthermia, susceptibility to, 1 | |
| | | Single nucleotide variant (missense variant) | not provided +8 more | GConflicting classifications of pathogenicity |
| | | Single nucleotide variant (missense variant) | Congenital myopathy with fiber type disproportion +7 more | |
| | | Single nucleotide variant (missense variant) | Malignant hyperthermia, susceptibility to, 1 | |
| | | Single nucleotide variant (missense variant) | RYR1-related myopathy +8 more | GConflicting classifications of pathogenicity |
| | | Duplication (frameshift variant) | RYR1-related disorder +6 more | GPathogenic/Likely pathogenic |
| | | Single nucleotide variant (missense variant) | RYR1-related disorder +7 more | |
| | | Single nucleotide variant (missense variant) | Malignant hyperthermia, susceptibility to, 1 | |